Gold prices tick higher on fresh US tariff threats, Fed rate cut hopes
Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Ofr at SI-BONE, Inc. (NASDAQ:SIBN), sold 3,127 shares of common stock on July 2, 2025, for approximately $57,202. The sales were executed in multiple transactions at prices ranging from $18.07 to $18.44.
Pisetsky’s transactions involved three sales. He sold 34 shares at $18.375, 1,795 shares at a weighted average price of $18.3125, and 1,298 shares at a weighted average price of $18.2644.
Following these transactions, Pisetsky directly owns 261,681 shares of SI-BONE, Inc. common stock, which includes 145,043 shares issuable on the settlement of restricted stock units. According to InvestingPro data, analysts maintain a strong bullish stance on the stock, with a consensus target suggesting significant upside potential. Get deeper insights into insider trading patterns and 7+ additional exclusive ProTips with an InvestingPro subscription.
The sales reported on the Form 4 represent shares required to be sold by Pisetsky to cover tax withholding obligations in connection with the vesting of restricted stock units and do not represent a discretionary trade by the reporting person. The company maintains a GREAT financial health score according to InvestingPro analysis, with strong liquidity metrics and solid growth momentum.
In other recent news, SI-BONE Inc. reported its first-quarter 2025 financial results, revealing a revenue of $47.3 million, which surpassed the projections of both Cantor Fitzgerald and FactSet, set at $45.1 million. This represents a year-over-year growth of approximately 25%, driven by a 27% increase in U.S. revenue. The company also reported a positive adjusted EBITDA of $0.5 million, significantly exceeding the consensus expectation of a $2.6 million loss. Following these results, JMP Securities reiterated its Market Outperform rating with a $32.00 price target, and Cantor Fitzgerald maintained its Overweight rating with a $25.00 price target.
Additionally, SI-BONE increased the higher end of its full-year revenue forecast, reflecting confidence in its growth trajectory. The company’s active U.S. surgeon count rose to over 1,400, marking a 27% increase from the previous year. Analyst firms highlighted the company’s ability to exceed expectations and effectively manage profitability metrics, contributing to a positive outlook. SI-BONE’s gross profit reached $37.7 million, with a gross margin of 79.7%, up 80 basis points year-over-year. The company is also preparing for the launch of a new SI joint fusion solution in 2026, aiming to further bolster its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.